Using novel point-of-care diagnostic tests and mathematical modelling to achieve hepatitis B elimination: The Rapid B Study [ 1/1/2021 - 12/31/2022 ]

Research Grant

Brief description Liver cancer is increasing rapidly in Australia and globally and depite hepatitis B virus infection being the leading cause, treatment rates are low. We have developed innovative point-of-care blood tests that use a single droplet of blood to measure liver damage, that will help overcome barriers to treatment uptake worldwide. The Rapid B Study will use mathematical modelling to investigate the most cost-effective way to combine these novel tests with treatment to reduce liver cancer deaths.

Funding Amount $381,948

Funding Scheme Ideas Grants

Chief Investigator Dr Jessica Howell

Notes Ideas Grants